01:15 , Jan 12, 2019 |  BioCentury  |  Finance

JPM jump-starts 2019

About three quarters of the more than 200 biopharma companies presenting at the 2019 J.P. Morgan Healthcare Conference saw their stock prices rise last week. Leading the pack was the 53% jump by Insmed Inc....
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech companies...
22:09 , Dec 17, 2018 |  BC Extra  |  Company News

Management tracks: Vertex’s Graney joins Generation Bio

Tom Graney has left Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as CFO to take on the same role at non-viral gene therapy company Generation Bio Co. (Cambridge, Mass.). Ian Smith, Vertex EVP and COO and former CFO,...
18:28 , Nov 30, 2018 |  BC Week In Review  |  Financial News

Follow-on roundup: Acadia raises $275M, Rocket pockets $55M

CNS company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and gene therapy company Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) each priced follow-ons late Nov. 27, raising $275 million and $55 million, respectively. Acadia markets Nuplazid pimavanserin, a small molecule serotonin...
22:43 , Nov 28, 2018 |  BC Extra  |  Financial News

Follow-on roundup: Acadia raises $275M, Rocket pockets $55M

CNS company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and gene therapy company Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) each priced follow-ons late Tuesday, raising $275 million and $55 million, respectively. Acadia markets Nuplazid pimavanserin, a small molecule serotonin receptor...
22:55 , Oct 30, 2018 |  BC Extra  |  Company News

Management tracks: Blueprint, Clovis

Ahead of the anticipated 2019 launch of avapritinib, Blueprint Medicines Corp. (NASDAQ:BPMC) hired Christina Rossi into the newly created role of chief commercial officer. She was the multiple sclerosis business unit head of North America...
23:48 , Oct 15, 2018 |  BC Extra  |  Company News

Management tracks: Rhythm, Redpin

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) hired Murray Stewart as CMO of the metabolic disorder company. Stewart was CMO of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) until 2017 when he became head of R&D at Novelion Therapeutics Inc. (NASDAQ:NVLN)....
21:55 , Oct 8, 2018 |  BC Extra  |  Company News

Management tracks: As Akcea shifts to commercialization, Crooke resigns from board

Akcea Therapeutics Inc. (NASDAQ:AKCA) said Stanley Crooke, founder, chairman and CEO of parent company Ionis Pharmaceuticals Inc. (NASDAQ:IONS), resigned from Akcea's board. Ionis CBO Damien McDevitt will take Crooke's place on Akcea's board. An Ionis...
21:33 , Sep 26, 2018 |  BC Extra  |  Company News

Management tracks: Merck clears path for Frazier to remain CEO

The board of Merck & Co. Inc. (NYSE:MRK) rescinded a 28-year-old policy that required CEOs to retire at age 65. CEO Kenneth Frazier, who turns 65 in December 2019, has agreed to stay in his...
16:25 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

FDA: No new safety concerns for Acadia's PD psychosis drug

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) rose $4.01 (27%) to $19.11 on Sept. 20, adding more than $500 million in market cap, after an FDA safety review of the company's Nuplazid pimavanserin found postmarketing safety data were...